Merz Pharmaceuticals
Closed portfolio with a later-stage archive tilt
According to ClinicalTrials.gov-derived indexes, Merz Pharmaceuticals sits in the top decile of US sponsors by registered trial count (#842 of 15,742 sponsors by registered trial count).
Merz Pharmaceuticals: 17 sponsored US clinical trials, none currently recruiting.
Merz Pharmaceuticals sponsors 17 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 15 completed. 13 of these trials are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Post-stroke Spasticity of the Upper Limb, with 1 trials.
Top-decile sponsor footprint
Merz Pharmaceuticals ranks in the top decile of sponsors by registered trial count (#842 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
15 of 16 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (93.8%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Indexed trials (enrollment closed)
17 total, page 1 of 1
Study to Compare the Efficacy and Safety of NT 201 (Botulinum Toxin) With Placebo for the Treatment of Lower Limb Spasticity Caused by Stroke or Traumatic Brain Injury
NCT03992404
A Study to Investigate the Efficacy and Safety of NT 201 (Botulinum Toxin) Compared With Placebo for the Treatment of Adult Participants With Essential Tremor in the Arm
NCT04766723
Botulinum Toxin A to Treat Arm Tremor
NCT02207946
Dose-response Study of Efficacy and Safety of Botulinum Toxin Type A to Treat Spasticity of the Arm(s) or of Arm(s) and Leg(s) in Cerebral Palsy
NCT02002884
Blepharospasm Patient Survey for Patients With Blepharospasm
NCT01686061
Efficacy and Safety Dose Titration Study of Botulinum Toxin Type A to Treat Spasticity in the Leg and Arm
NCT01603459
Open-Label Non-Inferiority Study Evaluating the Efficacy and Safety of Xeomin® in Subjects With Cervical Dystonia Flex
NCT01486264
Efficacy and Safety Study of Botulinum Toxin Type A Against Placebo to Treat Spasticity in the Leg After a Stroke
NCT01464307
Efficacy and Safety Study of Botulinum Toxin Type A Against Placebo to Treat Spasticity in the Arm After a Stroke
NCT01392300
Efficacy, Safety, Tolerability of Neramexane in Patients With Subjective Tinnitus
NCT00955799
Evaluation of Pharmacokinetics, Safety and Tolerability of Single and Multiple Oral Doses of Neramexane Mesylate in Healthy Japanese Subjects
NCT00983099
Open-Label, Long-Term Treatment Study, to Assess the Long-Term Safety and Tolerability and Efficacy of Neramexane in Patients With Subjective Tinnitus
NCT00827008
IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Glabellar Frown Lines No. 2
NCT00770029
IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Glabellar Frown Lines
NCT00770211
Safety and Efficacy of NT 201 (IncobotulinumtoxinA [Xeomin]) in the Treatment of Glabellar Frown Lines
NCT00512135
IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Blepharospasm
NCT00406367
IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Cervical Dystonia
NCT00407030
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 2 |
| Phase 3 | 12 |
| Phase 4 | 1 |
How the Merz Pharmaceuticals archive is shaped
17 indexed studies, none listed as recruiting (0% open); 15 completed (88%).
Phase mix: 13 late (III/IV) vs 3 early (I/II) (later-stage heavy).
Top condition: Post-stroke Spasticity of the Upper Limb (1 trial), 4 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Merz Pharmaceuticals: archived-pipeline peers nationwide
Peers matched on 17 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Merz Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 17 archived trials
- Achieve Life Sciences · 17 trials · 0% recruiting
- BioDelivery Sciences International · 17 trials · 6% recruiting
- Chugai Pharmaceutical · 17 trials · 24% recruiting
- ConvaTec · 17 trials · 18% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this Merz Pharmaceuticals page
17 registered trials is a research-attention snapshot, not an endorsement of Merz Pharmaceuticals or any single study.
- None of Merz Pharmaceuticals's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Post-stroke Spasticity of the Upper Limb is the condition Merz Pharmaceuticals studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Post-stroke Spasticity of the Upper Limb trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Merz Pharmaceuticals pipeline card: 17 registered trials from official public datasets.Report a data error.